Skip to content
Head to head

Zoetis vs Takeda Pharmaceutical

Side-by-side on the measures that matter, with a plain-English read. Full detail: ZTS · TAK

Updated 8 minutes ago

1-year performance, rebased to 100

ZTS -32.4%TAK +56.6%
Takeda Pharmaceutical edges it on the scoreable measures. Takeda Pharmaceutical has the highest Quant Rating (90); Takeda Pharmaceutical has done best over the past year (+57%).
ZTSTAK
Snapshot
SectorDrug Manufacturers - Specialty & Generic--
Last price79.1121.77
Change today-2.08%+1.68%
1-year return-30.7%+57.5%
Market cap$32.14B$69.76B
52-week range68.31 – 130.1213.92 – 22.07
Valuation
P/E (TTM)13.34311.00
P/E percentile, own 5-yr range9th100th
P/B9.731.50
Dividend yield2.64%1.44%
Profitability & growth
EPS (TTM)6.02-0.30
Net profit (TTM)$2.45B$-970.94M
Revenue (TTM)$9.49B$4.69T
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)-1.3%+6.7%
Gross margin71.6%65.8%
Operating margin37.7%14.3%
Net margin26.4%0.9%
Free cash flow (TTM)$2.24B$433.95B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership96.9%51.3%
Insider activity (12mo)41 buy / 5 sell19 buy / 31 sell
Short interest (% of float)4.0%0.1%
Analyst consensus30% buy / 70% hold (10)100% buy (1)
Analyst price target$89 (+13%)$50 (+132%)
StockVane view
StockVane Quant RatingE (14)C (90)
Company
Employees14,50047,029
Founded20121781

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.